TEDDY Study

TEDDY Study
Name	TEDDY Study
Abbreviation	TEDDY
Field	Pediatric epidemiology; Immunology
Start	2004
Participants	>8,600 children
Countries	United States; Finland; Sweden; Germany
Funding	National Institutes of Health; European Union

TEDDY Study The TEDDY Study is a large international prospective cohort study investigating environmental triggers of type 1 diabetes in genetically at-risk children. It links pediatric longitudinal clinical assessment with molecular assays, immunology, and environmental exposure measurement to identify precursors of autoimmunity and progression to clinical Type 1 diabetes; it engages multidisciplinary teams across institutions including National Institutes of Health, University of Florida, University of Colorado, University of Helsinki, Karolinska Institute, and University of Turku.

Overview

The TEDDY Study was launched to prospectively follow infants identified by HLA genotyping to determine environmental factors leading to islet autoimmunity and progression to Type 1 diabetes. It integrates clinical centers and coordinating hubs such as the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Diabetes and Digestive and Kidney Diseases, and collaborations with regional institutions like Turku University Hospital and Uppsala University Hospital. The consortium combines expertise from pediatric endocrinology units at Nemours Children's Health System, virology groups at Karolinska Institute, nutritional research at University of Turku, and biostatistics at Fred Hutchinson Cancer Center.

Study Design and Methods

TEDDY uses prospective cohort methodology with serial biospecimen collection, genotype screening, and standardized clinical assessments. At enrollment, infants undergo HLA genotyping performed by laboratories linked to centers such as University of Colorado School of Medicine and Children's Hospital of Philadelphia; follow-up includes serial measurements of autoantibodies, stool microbiome sequencing, dietary records, and environmental exposure logs coordinated by data centers like University of South Florida and University of Bristol. Laboratory methods incorporate assays refined at institutions including Joslin Diabetes Center, Broad Institute, Karolinska Institute, and Erasmus University Medical Center for immunophenotyping, metabolomics, and virome detection. Statistical analyses apply longitudinal models developed in partnership with groups at Fred Hutchinson Cancer Research Center, University of Pennsylvania, and Harvard T.H. Chan School of Public Health.

Participant Recruitment and Cohorts

Recruitment targeted newborns with HLA genotypes conferring increased risk, screened through newborn screening networks and birth registries in the United States, Finland, Sweden, and Germany. Cohort enrollment involved pediatric centers such as Seattle Children's Hospital, Children's Hospital of Philadelphia, St. Luke's Hospital, Oulu University Hospital, and University Hospital Schleswig-Holstein. The study maintains participation through family-centered protocols used at Johns Hopkins Hospital, Mayo Clinic, Massachusetts General Hospital, Baylor College of Medicine, and community outreach tied to organizations like JDRF, American Diabetes Association, and regional advocacy groups. Subcohorts include children progressing to persistent islet autoimmunity and those remaining autoantibody-negative, enabling nested case-control comparisons with data harmonized across data repositories managed by University of Florida and coordinating centers modeled on networks like Clinical and Translational Science Awards.

Key Findings and Outcomes

TEDDY reported associations between viral exposures and seroconversion to islet autoimmunity, dietary patterns including early introduction of cereals and probiotics, and gut microbiome shifts preceding autoantibody development. Publications from consortium investigators affiliated with Harvard Medical School, University of Cambridge, Karolinska Institute, University of Helsinki, and Yale University described temporal links between enterovirus detection and autoimmunity and metabolic signatures predictive of progression to Type 1 diabetes. Findings influenced vaccine and prevention discussions involving stakeholders such as World Health Organization, Centers for Disease Control and Prevention, European Medicines Agency, and patient advocacy organizations including JDRF and International Diabetes Federation. TEDDY outputs contributed to risk prediction tools used in trials like the Fr1da study and informed intervention design at centers such as TrialNet and initiatives coordinated by National Institute of Allergy and Infectious Diseases.

Ethical Considerations and Data Management

Ethical oversight was provided by institutional review boards at participating sites including University of Colorado, University of Helsinki, Karolinska Institute, University of Michigan, and Charité – Universitätsmedizin Berlin. Consent processes addressed genetic risk disclosure and secondary use of biospecimens, drawing on guidelines from bodies such as the World Medical Association and the Council for International Organizations of Medical Sciences. Data governance employed controlled-access repositories modeled on practices at dbGaP and federated systems used by the European Genome-phenome Archive; privacy protections referenced standards from Health Insurance Portability and Accountability Act and research ethics frameworks at National Institutes of Health.

Impact and Legacy

TEDDY's comprehensive biorepository and longitudinal dataset have become a resource for research on pediatric autoimmune disease etiology, shaping subsequent studies at institutions including Imperial College London, University of Toronto, Monash University, Charité – Universitätsmedizin Berlin, and University of Melbourne. Its methodology influenced cohort designs such as All of Us Research Program and informed policy discussions in forums like International Pediatric Association and workshops hosted by National Academy of Medicine. Ongoing collaborations continue to leverage TEDDY data for biomarker discovery, prevention trials, and translational efforts tied to clinical centers like Mount Sinai Health System, Cleveland Clinic, and Stanford University Medical Center.

Category:Longitudinal cohort studies Category:Autoimmune disease research